|
IN2014DN10515A
(enExample)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970508A4
(en)
*
|
2013-03-15 |
2016-12-14 |
Permeon Biologics Inc |
GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
CA2922979A1
(en)
*
|
2013-09-03 |
2015-03-12 |
Novimmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
EP3066133A1
(en)
*
|
2013-11-04 |
2016-09-14 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
JP6993228B2
(ja)
*
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
US20160176969A1
(en)
*
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
TWI656133B
(zh)
|
2014-12-19 |
2019-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
|
|
EP3237449A2
(en)
*
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
MA41279A
(fr)
|
2015-05-08 |
2021-04-28 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
EP3464370A1
(en)
|
2016-06-01 |
2019-04-10 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
WO2017210443A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd123 and cd3
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
IL265046B2
(en)
*
|
2016-08-30 |
2025-04-01 |
Xencor Inc |
Bispecific immunomodulatory antibodies that bind to costimulatory and checkpoint receptors
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
WO2018129522A1
(en)
|
2017-01-09 |
2018-07-12 |
Torch Therapeutics |
Conditionally effective bispecific therapeutics
|
|
EP4491234A3
(en)
|
2017-02-08 |
2025-04-09 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
BR112019017197A2
(pt)
|
2017-02-20 |
2020-04-14 |
Dragonfly Therapeutics, Inc. |
proteínas que se ligam a her2, nkg2d e cd16
|
|
JP2020510646A
(ja)
*
|
2017-02-20 |
2020-04-09 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
KR20200041834A
(ko)
|
2017-06-01 |
2020-04-22 |
젠코어 인코포레이티드 |
Cd123 및 cd3에 결합하는 이중특이성 항체
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
KR20200037388A
(ko)
*
|
2017-08-16 |
2020-04-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
|
|
IL311488A
(en)
*
|
2017-08-23 |
2024-05-01 |
Dragonfly Therapeutics Inc |
Proteins that bind D2NKG, 16CD, and tumor-associated antigen
|
|
CN111094356B
(zh)
*
|
2017-09-25 |
2022-11-01 |
苏州丁孚靶点生物技术有限公司 |
一种蛋白质异二聚体及其用途
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
AU2019218125B2
(en)
|
2018-02-08 |
2025-03-13 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
UY38080A
(es)
|
2018-02-08 |
2019-08-30 |
Amgen Inc |
FORMULACIÓN FARMACÉUTICA DE pH BAJO
|
|
PE20220278A1
(es)
|
2018-02-08 |
2022-02-25 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d
|
|
TW201942134A
(zh)
*
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
|
|
IL277375B2
(en)
|
2018-03-15 |
2025-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
RU2020135920A
(ru)
*
|
2018-04-05 |
2022-05-05 |
Новартис Аг |
Триспецифические связывающие молекулы против форм рака и пути их применения
|
|
WO2019200022A1
(en)
*
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
EP3781597A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
EP3781596A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
US20210230281A1
(en)
|
2018-04-27 |
2021-07-29 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
EA202091977A1
(ru)
*
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
WO2019232484A1
(en)
|
2018-06-01 |
2019-12-05 |
Compugen Ltd |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
|
CA3102256A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
KR20250151605A
(ko)
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
AU2019290192A1
(en)
*
|
2018-06-21 |
2021-01-07 |
Shattuck Labs, Inc. |
Heterodimeric proteins and uses thereof
|
|
WO2020018556A1
(en)
|
2018-07-16 |
2020-01-23 |
Amgen Inc. |
Method of treating multiple myeloma
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
KR20250112921A
(ko)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US20210340273A1
(en)
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
BR112021006783A2
(pt)
|
2018-10-12 |
2021-07-13 |
Xencor, Inc. |
proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer.
|
|
BR112021009835A2
(pt)
|
2018-11-30 |
2021-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
|
|
WO2020114479A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
江苏恒瑞医药股份有限公司 |
多特异性蛋白分子
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
CN113811549A
(zh)
|
2019-02-21 |
2021-12-17 |
Xencor股份有限公司 |
非靶向和靶向性il-10 fc融合蛋白
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
WO2020205516A1
(en)
|
2019-03-29 |
2020-10-08 |
Xencor, Inc. |
Dosing of a bispecific antibody that binds pd1 and ctla4
|
|
CA3139402A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Merus N.V. |
Variant domains for multimerizing proteins and separation thereof
|
|
CN114080397A
(zh)
|
2019-05-17 |
2022-02-22 |
Xencor股份有限公司 |
Il-7-fc融合蛋白
|
|
US20220241375A1
(en)
|
2019-05-20 |
2022-08-04 |
Cytune Pharma |
Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
KR20220010743A
(ko)
|
2019-05-21 |
2022-01-26 |
노파르티스 아게 |
Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
|
|
WO2020243315A1
(en)
*
|
2019-05-29 |
2020-12-03 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
US20220251222A1
(en)
*
|
2019-05-31 |
2022-08-11 |
The Johns Hopkins University |
IL-6Ralpha/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION
|
|
WO2020243479A1
(en)
|
2019-05-31 |
2020-12-03 |
The Johns Hopkins University |
Bispecific binding agents
|
|
WO2020259536A1
(zh)
*
|
2019-06-24 |
2020-12-30 |
南京金斯瑞生物科技有限公司 |
单克隆抗体-细胞因子融合蛋白二聚体及其应用
|
|
WO2021026387A2
(en)
|
2019-08-06 |
2021-02-11 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
CA3165045A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Adagene Ag |
Heterodimeric proteins with fc mutations
|
|
KR20220148175A
(ko)
|
2020-01-29 |
2022-11-04 |
인히브릭스, 인크. |
Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
|
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
|
|
CA3182697A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
EP4545569A3
(en)
*
|
2020-06-30 |
2025-10-08 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
KR20220014531A
(ko)
*
|
2020-07-29 |
2022-02-07 |
(주)메디톡스 |
헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법
|
|
JP7773528B2
(ja)
|
2020-08-19 |
2025-11-19 |
ゼンコア インコーポレイテッド |
抗ｃｄ２８組成物
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
WO2022061240A1
(en)
*
|
2020-09-21 |
2022-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Heteromultimeric proteins for reducing ige-dependent allergic effector cell activation
|
|
AR123767A1
(es)
|
2020-10-13 |
2023-01-11 |
Janssen Biotech Inc |
Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
|
|
US20220135684A1
(en)
|
2020-10-14 |
2022-05-05 |
Xencor, Inc. |
Bispecific antibodies that bind pd-l1 and cd28
|
|
EP4232478A1
(en)
|
2020-10-23 |
2023-08-30 |
Xencor, Inc. |
Anti-cd20 antibodies and therapeutic uses thereof
|
|
EP4232068A1
(en)
|
2020-10-26 |
2023-08-30 |
Cytune Pharma |
IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
|
|
EP4232069A1
(en)
|
2020-10-26 |
2023-08-30 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
WO2022097065A2
(en)
*
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
US20220144956A1
(en)
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
|
|
CA3197104A1
(en)
*
|
2020-11-11 |
2022-05-19 |
Hq Han |
Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
|
|
US20240067727A1
(en)
|
2020-12-17 |
2024-02-29 |
Ose Immunotherapeutics |
Bifunctional anti-pd1/il-7 molecules
|
|
US20220227867A1
(en)
|
2020-12-24 |
2022-07-21 |
Xencor, Inc. |
ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
CA3213917A1
(en)
|
2021-04-09 |
2022-10-13 |
Nicolas Poirier |
New scaffold for bifunctional molecules with improved properties
|
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
EP4328243A4
(en)
*
|
2021-04-20 |
2025-05-21 |
Korea University Research and Business Foundation |
Asymmetric antibody with improved cytotoxicity against cancer cell
|
|
CN115925967A
(zh)
|
2021-04-22 |
2023-04-07 |
广东菲鹏制药股份有限公司 |
双特异性多功能融合多肽
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
EP4355784A1
(en)
|
2021-06-15 |
2024-04-24 |
Xencor, Inc. |
Heterodimeric antibodies that bind claudin18.2 and cd3
|
|
KR20240023123A
(ko)
|
2021-06-22 |
2024-02-20 |
노파르티스 아게 |
화농성 한선염의 치료에 사용하기 위한 이중특이적 항체
|
|
MX2023015444A
(es)
*
|
2021-06-23 |
2024-04-29 |
Cytune Pharma |
Inmunocitocinas a base de interleucina-15.
|
|
EP4362984A1
(en)
|
2021-07-02 |
2024-05-08 |
Yale University |
Compositions and methods for treating cancers
|
|
US20230146665A1
(en)
|
2021-07-27 |
2023-05-11 |
Xencor, Inc. |
Il-18-fc fusion proteins
|
|
WO2023017191A1
(en)
|
2021-08-13 |
2023-02-16 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
|
|
IL310941A
(en)
*
|
2021-08-25 |
2024-04-01 |
Biograph 55 Inc |
Methods for the treatment of cancer associated with immunosuppressive B cells
|
|
WO2023028162A1
(en)
*
|
2021-08-25 |
2023-03-02 |
Biograph 55, Inc. |
Antibodies targeting immunosuppressive b cells
|
|
WO2023034864A1
(en)
|
2021-08-31 |
2023-03-09 |
Yale University |
Compositions and methods for treating cancers
|
|
JP2024534620A
(ja)
|
2021-09-27 |
2024-09-20 |
ゼンコア インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）結合ドメイン組成物
|
|
KR20240099376A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
|
|
WO2023081915A1
(en)
|
2021-11-08 |
2023-05-11 |
Xencor, Inc. |
Il-8 as a predictive biomarker and methods of use thereof for the treatment of cancer
|
|
CA3240046A1
(en)
|
2021-12-14 |
2023-06-22 |
Cdr-Life Ag |
Dual mhc-targeting t cell engager
|
|
US12365743B2
(en)
|
2022-02-23 |
2025-07-22 |
Xencor, Inc. |
Anti-CD28 x anti-PSMA antibodies
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
WO2023196905A1
(en)
|
2022-04-07 |
2023-10-12 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AU2023251832A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
US20230383012A1
(en)
|
2022-04-13 |
2023-11-30 |
Xencor, Inc. |
Antibodies that bind pd-l1, pd-l2, and/or cd28
|
|
EP4514846A1
(en)
|
2022-04-26 |
2025-03-05 |
Novartis AG |
Multispecific antibodies targeting il-13 and il-18
|
|
EP4547710A1
(en)
|
2022-07-01 |
2025-05-07 |
ALK-Abelló A/S |
Displacers of ige-fceri
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
US12161673B2
(en)
|
2022-09-14 |
2024-12-10 |
Cdr-Life Ag |
MAGE-A4 peptide dual T cell engagers
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
WO2024102645A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer
|
|
WO2024102693A2
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Il-18-fc fusion proteins
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
EP4694916A1
(en)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
AR133676A1
(es)
|
2023-08-28 |
2025-10-22 |
Xencor Inc |
Combiterapia de anti-cd20 x anti-cd28
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025075057A1
(ja)
*
|
2023-10-02 |
2025-04-10 |
国立大学法人 熊本大学 |
ポリペプチドの会合体形成抑制方法
|
|
WO2025085447A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Pd-1 targeted il18-fc fusion proteins
|
|
WO2025157132A1
(en)
|
2024-01-23 |
2025-07-31 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
|
|
WO2025183172A1
(ja)
*
|
2024-02-28 |
2025-09-04 |
旭化成株式会社 |
等電点が改変されたドメインを有する抗体
|
|
WO2025210181A1
(en)
|
2024-04-04 |
2025-10-09 |
Cdr-Life Ag |
Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
|
|
WO2025215160A1
(en)
|
2024-04-11 |
2025-10-16 |
Cdr-Life Ag |
Antigen binding proteins targeting an hla-restricted prame peptide
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
US20250361311A1
(en)
|
2024-05-24 |
2025-11-27 |
Xencor, Inc. |
Anti-tnf-like ligand 1a (tl1a) antibodies
|
|
US20250376536A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
WO2025255405A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Anti-fap antibodies and uses thereof
|
|
WO2025262265A1
(en)
|
2024-06-21 |
2025-12-26 |
Etablissement Francais Du Sang |
Chimeric molecules comprising an anti-fibrin antibody and an antithrombotic molecule
|